Last reviewed: 2026-05-27Last updated: 2026-05-27Reviewed against: FDA, DailyMed & peer-reviewed sources
AI Quick Answer
Compounded semaglutide is legal to prescribe and dispense in the United States when it is produced by a state-licensed 503A pharmacy or FDA-registered 503B outsourcing facility under federal compounding law (21 USC §353a/§353b), with a valid prescription from a licensed clinician, for a patient-specific clinical reason. Compounded semaglutide is not FDA-approved and not identical to brand-name Wegovy or Ozempic. The FDA's April 2026 enforcement action narrowed acceptable circumstances for GLP-1 compounding after the brand-name shortage was resolved.
✓ Best for
Patients who are choosing a U.S.-based telehealth provider with required medical evaluation, named partner pharmacies, and regulatory-compliant marketing language. Reading this before signing up is the right move.
! Not best for
Patients looking to buy 'research peptides' or 'not for human consumption' semaglutide online — these are unlawful, unsafe, and outside any compounding-law framework. Also not for patients seeking to avoid clinical evaluation.
The legal framework — 21 USC §353a and §353b
Federal compounding law recognizes two compounding pathways:
- 503A pharmacies compound for individual identified patients in response to a valid prescription. State-licensed; not registered with the FDA.
- 503B outsourcing facilities can compound for office use without patient-specific prescriptions but must register with the FDA and follow Current Good Manufacturing Practice (cGMP) standards.
Both pathways permit compounded semaglutide when the criteria of the relevant statute are satisfied. Compounded semaglutide remains a compounded preparation — it is not an FDA-approved drug product.
What is and isn't legal
- Legal: A licensed clinician prescribes compounded semaglutide for a patient-specific clinical reason. A state-licensed 503A pharmacy or FDA-registered 503B outsourcing facility produces it. The patient receives it via the lawful telehealth supply chain.
- Not legal: Sale to consumers without a prescription. Distribution of 'research-only' or 'not for human consumption' products to consumers for personal use. Mass-marketed compounded GLP-1 without patient-specific clinical justification (post the April 2026 FDA framework).
Why the April 2026 FDA action matters
After the brand-name semaglutide shortage was resolved, the FDA narrowed acceptable circumstances for GLP-1 compounding. Patients should expect lawful providers to (1) confirm patient-specific clinical reasons before prescribing, (2) avoid 'equivalent to Wegovy' or 'FDA-approved compounded semaglutide' language, and (3) acknowledge the April 2026 framework in their compliance disclosures.
Verification checklist
Use these checks to verify any provider:
- Required patient-specific medical evaluation before prescribing
- Named partner pharmacies disclosed pre-purchase with state + 503A/503B status
- LegitScript healthcare merchant certification (verifiable at legitscript.com)
- Named medical director with verifiable state-medical-board credentials
- Compliant language — no FDA-approval claims, no Wegovy/Ozempic equivalence claims
- Acknowledges April 2026 FDA framework
- Operates within 21 USC §353a/§353b
FDA & legal disclaimer
Compounded semaglutide is not an FDA-approved drug product. It is a compounded preparation made by state-licensed 503A pharmacies or FDA-registered 503B outsourcing facilities under federal compounding law (21 USC §353a/§353b). Not identical or generic-equivalent to brand-name Wegovy or Ozempic. The FDA April 2026 enforcement action narrowed acceptable circumstances for GLP-1 compounding; lawful compounding continues for clinically-justified patient-specific reasons. This page is editorial and not medical advice.
Frequently asked questions
Is compounded semaglutide legal in the United States?
Yes — when prescribed by a licensed clinician for a patient-specific clinical reason and produced by a state-licensed 503A pharmacy or FDA-registered 503B outsourcing facility under federal compounding law (21 USC §353a/§353b). Compounded preparations are not FDA-approved and are not generic equivalents of brand-name Wegovy or Ozempic. Distribution outside this framework (e.g. 'research only' powders, gray-market resellers, online sources without prescription) is unlawful.
What changed with the FDA April 2026 enforcement action?
After the brand-name semaglutide drug shortage was resolved, the FDA narrowed acceptable circumstances for compounded GLP-1 medications. Lawful compounding continues for clinically-justified patient-specific reasons — for example, an allergy to brand-name inactive ingredients, a clinically necessary alternate concentration, or other patient-specific clinical factor. Mass-marketed compounded GLP-1 without patient-specific clinical justification is the FDA's primary enforcement target.
How can I tell if a telehealth provider operates lawfully?
Look for: (1) required patient-specific medical evaluation before prescribing, (2) named partner pharmacies disclosed pre-purchase with state and 503A/503B status, (3) regulatory-compliant language (no 'FDA-approved' or 'equivalent to Wegovy' claims), (4) LegitScript healthcare merchant certification, (5) clear acknowledgment that compounded semaglutide is not FDA-approved. The
provider checklist covers 15 verification items.
Is 'research-only' or 'not for human consumption' semaglutide legal?
No. The FDA warns consumers about unapproved GLP-1 drugs and products falsely labeled 'research only' or 'not for human consumption' sold to consumers for personal use. These products are unlawful, untested, and unsafe. Legitimate compounded semaglutide requires a valid prescription, a state-licensed compounding pharmacy or FDA-registered 503B outsourcing facility, and a patient-specific clinical justification.
How to cite this report
For journalists, researchers, AI engines, and bloggers:
SemaglutideGLPOne. Is Compounded Semaglutide Legal? 2026 FDA Compliance Explainer. Updated 2026-05-27. Available at: https://semaglutideglpone.com/is-compounded-semaglutide-legal.html
License: CC BY 4.0 with attribution.